Anaptys Announces Participation in September Investor Conferences
29 Agosto 2024 - 8:15AM
AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology
company focused on delivering innovative immunology therapeutics,
today announced that Daniel Faga, president and chief executive
officer of Anaptys, and/or other members of its senior management
team, are scheduled to participate in multiple upcoming investor
conferences:
2024 Wells Fargo Healthcare Conference, Boston,
MA
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Thursday, Sept. 5, 2024 at 10:15am ET / 7:15am
PT
Stifel 2024 Virtual Immunology and Inflammation
Summit
- Format – Fireside chat
- Date and Time – Tuesday, Sept. 17, 2024 at 1:30pm ET / 10:30am
PT
2024 Cantor Fitzgerald Global Healthcare
Conference, New York, NY
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Wednesday, Sept. 18, 2024 at 9:45am ET / 6:45am
PT
Live webcasts of the fireside chats will be available on the
investor section of the Anaptys website at
http://ir.anaptysbio.com/events. Replays of the webcasts will be
available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on
delivering innovative immunology therapeutics. It is developing
immune cell modulators for autoimmune and inflammatory diseases,
including two checkpoint agonists: ANB032, its BTLA agonist, in a
Phase 2b trial for the treatment of atopic dermatitis and
rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment
of rheumatoid arthritis and in a Phase 2 trial for the treatment of
ulcerative colitis. It also has other immune cell modulator
candidates in its portfolio, including ANB033, an anti-CD122
antagonist antibody, entering a Phase 1 trial and ANB101, a BDCA2
modulator antibody, in preclinical development. In addition,
Anaptys has developed two cytokine antagonists available for
out-licensing: imsidolimab, an anti-IL-36R antagonist, that has
completed Phase 3 trials for the treatment of generalized pustular
psoriasis, and etokimab, an anti-IL-33 antagonist that is Phase 2/3
ready. Anaptys has also discovered multiple therapeutic antibodies
licensed to GSK in a financial collaboration for immuno-oncology,
including an anti-PD-1 antagonist antibody (Jemperli
(dostarlimab-gxly)) and an anti-TIM-3 antagonist antibody
(cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or
follow us on LinkedIn and X.
Contact:Nick MontemaranoSenior Director,
Investor Relations and Strategic Communications
858.732.0178investors@anaptysbio.com
AnaptysBio (NASDAQ:ANAB)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
AnaptysBio (NASDAQ:ANAB)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024